Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Down - Should You Sell?

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) shares gapped down before the market opened on Friday . The stock had previously closed at $2.15, but opened at $2.05. Autolus Therapeutics shares last traded at $2.12, with a volume of 439,481 shares traded.

Wall Street Analysts Forecast Growth

AUTL has been the subject of a number of recent analyst reports. Wells Fargo & Company lowered their price target on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a research note on Friday, March 21st. Needham & Company LLC reaffirmed a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research note on Thursday. Finally, Truist Financial reduced their price target on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Autolus Therapeutics presently has an average rating of "Buy" and an average price target of $9.32.

Autolus Therapeutics Trading Down 3.3%

The company has a fifty day moving average price of $1.55 and a two-hundred day moving average price of $1.94. The firm has a market cap of $545.59 million, a P/E ratio of -1.69 and a beta of 1.76.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The business had revenue of $8.98 million for the quarter, compared to analysts' expectations of $1.59 million. As a group, sell-side analysts expect that Autolus Therapeutics plc will post -0.94 EPS for the current year.

Institutional Trading of Autolus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of AUTL. Jane Street Group LLC bought a new position in shares of Autolus Therapeutics during the 4th quarter worth approximately $26,000. Barclays PLC grew its position in Autolus Therapeutics by 1,094.3% in the fourth quarter. Barclays PLC now owns 11,859 shares of the company's stock valued at $28,000 after purchasing an additional 10,866 shares in the last quarter. Invesco Ltd. increased its stake in Autolus Therapeutics by 53.3% in the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company's stock valued at $51,000 after buying an additional 11,381 shares during the last quarter. Daiwa Securities Group Inc. lifted its position in Autolus Therapeutics by 55.5% during the 4th quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock worth $56,000 after buying an additional 8,479 shares in the last quarter. Finally, Virtus ETF Advisers LLC lifted its position in Autolus Therapeutics by 29.9% during the 4th quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company's stock worth $62,000 after buying an additional 6,081 shares in the last quarter. Institutional investors and hedge funds own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.